Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study.

Dorota Zarębska-MichalukJerzy JaroszewiczMagdalena RogalskaDiana MartonikPaweł PabjanAleksandra Berkan-KawińskaBeata BolewskaBarbara Oczko-GrzesikDorota KozielewiczMagdalena Tudrujek-ZdunekJustyna KowalskaAnna Moniuszko-MalinowskaKrzysztof KłosMarta RoratPiotr LeszczyńskiAnna PiekarskaJoanna PolańskaRobert Flisiak

Published in: Journal of inflammation research (2021)

In patients with severe course of COVID-19, particularly those developing cytokine storm, administration of TCZ provides a significantly better effect than DEX regarding survival, clinical improvement, and hospital discharge rate. The combination of TCZ and DEX does not improve therapy effectiveness in patients with severe COVID-19 compared to the administration of TCZ alone.

Keyphrases

coronavirus disease
sars cov
early onset
randomized controlled trial
systematic review
rheumatoid arthritis
respiratory syndrome coronavirus
drug induced
stem cells
systemic lupus erythematosus
cell therapy